At Olema, we are committed to improving outcomes for women with metastatic breast cancer. Our lead asset, palazestrant (OP-1250), is a novel investigational agent with combined activity as both an advanced complete estrogen receptor antagonist, (a next-generation CERAN), and a selective estrogen receptor degrader, or SERD, which we believe will drive deeper, more durable responses than currently available therapies. 

You can find information about our clinical trials and impact on patients at our website: https://olema.com/

Please join us in this fight by making your donation today.  

Onto Something Big, Together!